Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma

Cancer Letters

Volumn 298, Issue 2, 2010, Pages 195-203

  Chiang, Chun Te ^a   Yeh, Pei Yen ^a   Gao, Ming ^a   Chen, Chun Wei ^a   Yeh, Ling Chun ^a   Feng, Wen Chi ^a   Kuo, Sung Hsin ^a   Hsu, Chih Hung ^a   Lu, Yen Shen ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Gemcitabine; MTOR; Non Hodgkin lymphoma; Paclitaxel; RAD001

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; EVEROLIMUS; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; PACLITAXEL; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LYMPHOMA, NON-HODGKIN; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 77957938917     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.005     Document Type: Article

References (32)

1. Hauke R.J., Armitage J.O. Treatment of non-Hodgkin lymphoma. Curr. Opin. Oncol. 2000, 12:412-418.
2. Gisselbrecht C., Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin. Oncol. 2004, 31:12-16.
3. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
4. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
5. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updates 2008, 11:32-50.
6. Rudelius M., Pittaluga S., Nishizuka S., Pham T.H.T., Fend F., Jaffe E.S., Quintanilla-Martinez L., Raffeld M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
7. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., Atizado V., Al-Dayel F., Belgaumi A., El-Solh H., Ezzat A., Bavi P., Al-Kuraya K.S. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
8. Vega F., Medeiros L.J., Leventaki V., Atwell C., Cho-Vega J.H., Tian L., Claret F.-X., Rassidakis G.Z. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006, 66:6589-6597.
9. Ansell S.M., Inwards D.J., Rowland K.M., Flynn P.J., Morton R.F., Moore D.F., Kaufmann S.H., Ghobrial I., Kurtin P.J., Maurer M., Allmer C., Witzig T.E. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the north central cancer treatment group. Cancer 2008, 113:508-514.
10. Hess G., Romaguera J.E., Verhoef G., Herbrecht R., Crump M., Strahs A., Clancy J., Hewes B., Coiffier B. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J. Clin. Oncol. (Meeting Abstracts) 2008, 26:8513.
11. Rizzieri D.A., Feldman E., DiPersio J.F., Gabrail N., Stock W., Strair R., Rivera V.M., Albitar M., Bedrosian C.L., Giles F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2008, 14:2756-2762.
12. Smith S.M., Pro B., Cisneros A., Smith S., Stiff P., Lester E., Modi S., Dancey J.E., Vokes E.E., van Besien K. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J. Clin. Oncol. (Meeting Abstracts) 2008, 26:8514.
13. Witzig T.E., Geyer S.M., Ghobrial I., Inwards D.J., Fonseca R., Kurtin P., Ansell S.M., Luyun R., Flynn P.J., Morton R.F., Dakhil S.R., Gross H., Kaufmann S.H. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 2005, 23:5347-5356.
14. Yee K.W.L., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., Thomas D., Wierda W., Apostolidou E., Albitar M., O'Brien S., Andreeff M., Giles F.J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006, 12:5165-5173.
15. Wendel H.-G., Stanchina E.D., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
16. Haritunians T., Mori A., O'Kelly J., Luong Q.T., Giles F.J., Koeffler H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2006, 21:333-339.
17. Teachey D.T., Sheen C., Hall J., Ryan T., Brown V.I., Fish J., Reid G.S., Seif A.E., Norris R., Chang Y.J., Carroll M., Grupp S.A. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008, 112:2020-2023.
18. Emmanouilides C., Jazirehi A.R., Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother. Radiopharm. 2002, 17:621-630.
19. Dumontet C., Morschhauser F., Solal-Celigny P., Bouafia F., Bourgeois E., Thieblemont C., Leleu X., Hequet O., Salles G., Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br. J. Haematol. 2001, 113:772-778.
20. Fossa A., Santoro A., Hiddemann W., Truemper L., Niederle N., Buksmaui S., Bonadonna G., Seeber S., Nowrousian M.R. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 1999, 17:3786-3792.
21. Romaguera J.E., Rodriguez M.A., Hagemeister F.B., McLaughlin P., Rodriguez J., Preti A., Younes A., Sarris A.H., Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest. New Drugs 1999, 17:187-192.
22. Younes A., Rodriguez M.A., McLaughlin P., North L., Sarris A.H., Pate O., Hagemeister F.B., Romaguera J., Preti A., Bachier C., Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leukemia Lymphoma 1997, 26:77-82.
23. Balzarotti M., Santoro A., Tondini C., Fornier M., Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann. Oncol. 1996, 7:970-972.
24. Chiang C.-T., Way T.-D., Lin J.-K. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin. Mol. Cancer Ther. 2007, 6:2127-2138.
25. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
26. Yang S.H., Lin Z.Z., Kuo S.H., Cheng A.L. Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma. Am. J. Hematol. 2009, 84:457-459.
27. Pommier Y., Sordet O., Antony S., Hayward R.L., Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004, 23:2934-2949.
28. Adams K.W., Cooper G.M. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 2007, 282:6192-6200.
29. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O Reilly T., Natt F., Hall J., Lane H.A., Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
30. Mills J.R., Hippo Y., Robert F., Chen S.M., Malina A., Lin C.J., Trojahn U., Wendel H.G., Charest A., Bronson R.T., Kogan S.C., Nadon R., Housman D.E., Lowe S.W., Pelletier J. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA 2008, 105:10853-10858.
31. Wei G., Twomey D., Lamb J., Schlis K., Agarwal J., Stam R.W., Opferman J.T., Sallan S.E., den Boer M.L., Pieters R., Golub T.R., Armstrong S.A. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331-342.
32. Faber A.C., Li D., Song Y., Liang M.C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.M., Garcia-Echeverria C., Wong K.K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA 2009, 106:19503-19508.